NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-24-042 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to enhance the capability of NCATS CTSA Program KL2 scholars and recipients of diversity and re-entry supplements supported by the CTSA Program to conduct research as they complete the transition to fully independent academic translational scientists. These R03 grants will support different clinical and translational science research projects, including pilot and feasibility studies; secondary data analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support submission of a subsequent R01, or equivalent, application.
Funding Opportunity PAR-24-069 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences.
Notice NOT-CA-24-008 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-040 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. Specifically, this FOA will support the development of exportable training modules designed to enhance training of the biomedical research workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS.
Funding Opportunity RFA-NS-24-029 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.
Funding Opportunity RFA-TR-23-018 from the NIH Guide for Grants and Contracts. This NOFO provides support using the STTR cooperative agreement mechanisms for the development of MATChS. Applications considered responsive to this would include those proposing research and development of tools and turnkey technologies for higher throughput automated measures with on-line sensing, rapid acquisition and analysis of data to reduce manual handling. Funded projects will result in an increased availability of miniaturized automated tissue chip platforms for use in drug development and across multiple applications as a major research tool in biomedical research laboratories. As a cooperative agreement, small business concerns (SBCs) will be expected to develop milestones and benchmarks, and work with NIH staff towards progress in the aims of the project to develop an automated system and demonstrable pathways to commercialization.
Funding Opportunity RFA-TR-23-017 from the NIH Guide for Grants and Contracts. This NOFO provides support using the SBIR cooperative agreement mechanisms for the development of MATChS. Applications considered responsive to this would include those proposing research and development of tools and turnkey technologies for higher throughput automated measures with on-line sensing, rapid acquisition and analysis of data to reduce manual handling. Funded projects will result in an increased availability of miniaturized automated tissue chip platforms for use in drug development and across multiple applications as a major research tool in biomedical research laboratories. As a cooperative agreement, small business concerns (SBCs) will be expected to develop milestones and benchmarks, and work with NIH staff towards progress in the aims of the project to develop an automated system and demonstrable pathways to commercialization.
Funding Opportunity PAR-24-065 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health disparities, and translation research that address the mission of the Institute. This FOA requires a minimum of three interrelated research projects that investigate a complex biomedical theme or research question. The projects may be supported by core units, if justified, to facilitate economy of effort, space, and equipment. The NHLBI provides support for Program Project Grants (PPGs) in the belief that collaborative research efforts can accelerate the acquisition of knowledge more effectively than a simple aggregate of research projects that have no interaction or thematic integration. NHLBI is particularly interested in encouraging new scientific directions in PPGs. Use of the P01 activity code is viewed as an opportunity to attract scientists who have not traditionally been supported by the NHLBI. Further, the PPG environment presents an opportunity for emerging scientific leaders to gain insight into how to lead a successful scientific Program, and applicants will have the opportunity to include a project led by an Early Stage Investigator (ESI). All projects in the Program must be interrelated and have objectives that address a central theme within the scientific mandate of the NHLBI.
Notice NOT-NS-24-034 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-014 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages exploratory and developmental research to better understand adolescent illicit fentanyl use and overdose patterns among youth at high risk for overdose. Research studies should identify targets for overdose prevention and substance use disorder (SUD) treatment and recovery. Research studies may use a variety of approaches (e.g., leveraging existing data sources, survey research, social network analysis, new methods development, feasibility research). Outcomes of interest include but are not limited to prevalence of overdose and reduction in substance use, particularly fentanyl use or use of drugs that are commonly laced with fentanyl; unintentional use/overdose, use/overdose by risk group, stigma, family and environmental risk and protective factors, treatment engagement, youth perceptions of substance use, and optimistic bias.
Notice NOT-CA-24-013 from the NIH Guide for Grants and Contracts
Notice NOT-ES-24-001 from the NIH Guide for Grants and Contracts
Notice NOT-AI-24-005 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-031 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials that will guide the expansion of effective, non-stigmatizing overdose prevention, SUD treatment and recovery services for adolescents. These studies could include examining changes in risk behaviors associated with overdose (e.g., using alone, carrying/using Naloxone). Outcomes of interest include but are not limited to harm reduction, recovery, treatment retention and effectiveness, quality of care, patient-centered outcomes, and implementation factors. The goal of this NOFO is to develop interventions that address effective, non-stigmatizing overdose prevention, SUD treatment and recovery services for youth that are effective, practical, cost-effective, scalable, and sustainable.
Notice NOT-DA-23-045 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-009 from the NIH Guide for Grants and Contracts
Notice NOT-HS-24-004 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-026 from the NIH Guide for Grants and Contracts
Notice NOT-MD-23-019 from the NIH Guide for Grants and Contracts